Hadir Rana
In the relentless battle against leukemia, a groundbreaking treatment has emerged that redefines how we harness the immune system: CAR-T cell therapy. This revolutionary approach doesn’t rely on external drugs to kill cancer—it transforms the patient’s own immune cells into precisionguided cancer assassins. CAR-T stands for Chimeric Antigen Receptor Tcell therapy. It’s a form of cellular immunotherapy where a patient’s T cells—white blood cells that play a central role in immune defense—are genetically modified to recognize and attack cancer cells. The process begins with leukapheresis, a procedure that extracts T cells from the patient’s blood. These cells are then sent to a specialized lab where they’re engineered to express chimeric antigen receptors (CARs) on their surface. These synthetic receptors allow the T cells to identify specific proteins (antigens) found on leukemia cells, such as CD19, a common marker in B-cell leukemias.